Your browser doesn't support javascript.
loading
Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction.
Crantford, John Clayton; Wood, Benjamin C; Claiborne, Jeffrey R; Ririe, Doug G; Couture, Daniel E; Thompson, James T; David, Lisa R.
Afiliación
  • Crantford JC; From the Departments of *Plastic and Reconstructive Surgery, †Anesthesiology, and ‡Neurosurgery, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
J Craniofac Surg ; 26(1): 104-7, 2015 Jan.
Article en En | MEDLINE | ID: mdl-25534062
BACKGROUND: Blood loss is the leading cause of mortality after major craniofacial surgery. Autologous blood donation, short-term normovolemic hemodilution, and intraoperative blood salvage have shown low efficacy in decreasing transfusions. Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively decreases the conversion of plasminogen to plasmin, thereby suppressing fibrinolysis. The purpose of this study was to investigate the impact that TXA administration has on intraoperative blood loss and blood product transfusion in pediatric patients undergoing cranial vault reconstruction. METHODS: An Internal Review Board-approved retrospective study was conducted on a consecutive series of pediatric patients undergoing cranial vault reconstruction from January 2009 to June 2012. Seventeen consecutive patients who received TXA at the time of cranial vault reconstruction were compared with 20 patients who did not receive TXA. Criteria for blood product transfusion were identical for both groups. Outcomes including perioperative blood loss, volume of blood transfused, and adverse effects were analyzed. RESULTS: The TXA group had a significantly lower perioperative blood loss (9.4 versus 21.1 mL/kg, P < 0.0001) and lower volume of perioperative mean blood product transfusion (12.8 versus 31.3 mL/kg, P < 0.0001) compared with the non-TXA group. There was no significant difference in demographic data, infection rate, change in preoperative to postoperative hematocrit, duration of surgery, or complication rates between the TXA and non-TXA groups. No drug-related adverse effects were identified in patients who received TXA. CONCLUSIONS: The use of TXA in pediatric cranial vault reconstruction significantly reduces perioperative blood loss and blood product transfusion requirements. The TXA administration is safe and may improve patient outcomes by decreasing the likelihood of adverse effects related to blood product transfusion.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácido Tranexámico / Procedimientos de Cirugía Plástica / Craneosinostosis / Antifibrinolíticos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Craniofac Surg Asunto de la revista: ODONTOLOGIA Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácido Tranexámico / Procedimientos de Cirugía Plástica / Craneosinostosis / Antifibrinolíticos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Craniofac Surg Asunto de la revista: ODONTOLOGIA Año: 2015 Tipo del documento: Article